Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Oktober 2025 15:05 ET | Quelle: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025.
09. September 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Castle will share new data on its TissueCypher Barrett’s Esophagus test via a podium presentation on Sept. 13 at the AFS 2025 Annual Meeting.
02. Mai 2025 16:30 ET | Quelle: Castle Biosciences, Inc.

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Castle Biosciences will share new data on its TissueCypher test for patients with Barrett’s esophagus at DDW 2025.
08. April 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month.
08. September 2021 09:00 ET | Quelle: Cernostics

Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay

Pittsburgh, PA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cernostics, pioneer of the worlds’ first precision medicine test to predict future development risk of esophageal cancer from Barrett’s esophagus...